Neurology · Internal Medicine · 2 h ago
Glucosamine use associated with dementia progression in retrospective health-record analysis
A retrospective UF Health analysis linked glucosamine use to a 25% higher likelihood of progression from mild cognitive impairment to dementia. The study included 2,750 glucosamine users with mild cognitive impairment; supporting laboratory findings suggest a metabolic mechanism but do not establish causality in humans.
- Glucosamine use was associated with 25% higher MCI-to-dementia progression likelihood.
- Mortality association appeared in established dementia, not mild cognitive impairment.
- Laboratory findings implicated excessive protein sugar tagging.
- Observational findings do not establish causality or justify automatic discontinuation.
University of Florida researchers analyzed deidentified UF Health records from 2012–2024 to examine associations between glucosamine use and outcomes in patients with mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD). Published in Nature Metabolism, the study also included mouse experiments and human brain tissue analyses. Reported glucosamine users represented 8% of each clinical group: 2,750 patients with MCI and 1,896 with ADRD. Total cohort sizes were not provided in the source report.
After adjustment for age, sex and demographics, glucosamine use was associated with a 25% higher likelihood of progression from MCI to dementia. Among patients with established ADRD, use was associated with a 25% higher mortality risk; this mortality association was not observed in the MCI group. Absolute risks, confidence intervals and individual follow-up duration were not reported in the source.
In mice, glucosamine increased intracellular protein sugar tagging and worsened recognition-related memory deficits; chemically suppressing this process improved memory performance. Human Alzheimer's brain specimens also showed greater sugar attachment than control tissue. These findings offer a possible mechanism but do not prove that supplementation accelerates dementia in humans. The retrospective associations remain susceptible to confounding, and the UF Health–provided report states that controlled human trials are needed. The findings alone do not establish that patients should discontinue glucosamine.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Metabolism (via ScienceDaily): Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.